Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907797 · ClinicalTrials.gov registry record · NA
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
A NA study of Leukemia and Acute Leukemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06907797: Recruiting NA study of Leukemia and Acute Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT06907797 is a NA study of Leukemia and Acute Leukemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 75 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06907797, a NA study of Leukemia and Acute Leukemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.
Primary Outcome
Defined as the proportion of completed post-tests compared to the overall total of 75. Retention feasibility is defined as ≥ 70% of post-test completions, or 53 completions.
Conditions Studied
Interventions
- BEHAVIORAL TRIAL Web-Based Application
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT06907797 shows while recruiting
NCT06907797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which TRIAL Web-Based Application is the first listed.
NCT06907797 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06907797 about?
NCT06907797 is a clinical study titled "Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing". This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.
What is the current status of trial NCT06907797?
This trial is currently recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2025-04-01. Estimated completion is 2027-06-30.
What conditions does trial NCT06907797 study?
This clinical trial studies the following conditions: Leukemia, Acute Leukemia.
What interventions are being tested in trial NCT06907797?
The interventions under investigation include: TRIAL Web-Based Application (BEHAVIORAL).
Who is sponsoring clinical trial NCT06907797?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907797 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06907797's enrollment target sits among peer trials
75 85th of 233 higher than 148 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
RECRUITING · NA
-
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
RECRUITING · NA
-
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI